\body Hematopoietic stem cells (HSC) self-renew and differentiate to form all blood cells throughout animal life. The intricate balance between these two characteristic stem cell states is required for maintaining hematopoietic homeostasis and responding to tissue injury. Stem cell population size is tightly regulated and thought to be dictated by rates of proliferation, relative frequency of differentiative versus self-renewal outcomes and apoptosis. Disruption of any of these processes could lead to stem cell exhaustion or increased risk of leukemogenesis (1) (2) (3) (4) (5) . However, the molecular events specifying stem cell population size are still poorly understood.
MicroRNAs are emerging as a class of important cellular regulators that mediate cell state with specific patterns of microRNA expression demarcating developmental or differentiation stages (6-8). They are transcribed as longer primary microRNAs and their maturation is dependent on the RNase III enzyme, Dicer (9-13). In the blood system, multiple microRNAs have been found to direct differentiation, e.g. miR-181 for T cells (14), miR-150 for B cells (15, 16) and miR-223 for granulocytes (17) (18) (19) . We have shown that miR-150, shunts megakaryocyte and erythrocyte common progenitors (MEP) toward megakaryocytes (20) . To date, all known microRNAs reinforce specific lineage outcome and no specific microRNAs are known to regulate the number of stem/progenitor cells in the hematopoietic system.
RESULTS

Hematopoietic ablation of Dicer impaired the hematopoietic stem/progenitor compartment
We hypothesized that microRNAs regulate HSCs and first evaluated this using a mouse with a conditional allele of the microRNA processing enzyme Dicer (10, 13 days. The day of the last pIpC injection was counted as day 0. The contribution to T, B
and myeloid lineages in the peripheral blood (PB) was monitored over time ( Figure 1A and B, Figure S1 ). While both mutant and control groups showed ~50% overall donor type (CD45.2+) reconstitution before pIpC injection, reconstitution by mutant marrow markedly declined after pIpC treatment, and remained reduced until 20 weeks postpIpC, when donor contribution was primarily stem-cell-derived. The reduction in reconstitution by mutant BM could also be observed in secondary transplant recipients ( Figure S1C ), underscoring the importance of Dicer in HSCs.
Two lines of evidence support the notion that HSPCs are impaired by Dicer loss, rather than the alternative possibility that the reduction in mutant marrow repopulation capacity is completely due to impairing multiple independent committed lineages. First, mutant marrow gave reduced donor cell contribution to the Lin -Kit + Sca + (LKS) population ( Figure 1C ), which contains all HSCs and multipotent progenitors. In addition, this reduction paralleled in magnitude the reduction in committed cell types. Second, the decline of mutant BM reconstitution occurred progressively after pIpC treatment over a period of 8-10 weeks ( Figure 1A) . Importantly, the drop in myeloid reconstitution was evident as early as 1 day after the last dose of pIpC (13 days after initiation of pIpC), while the lymphoid lineages were still intact at this time ( Figure S1D ). This is consistent with the difference in the turnover rate among these lineages, with the rapidly turning- Figure S4 ).
The notion that Dicer loss causes apoptosis in HSPCs predicts that stem cell niche could be vacated to allow engraftment of exogenous stem cells. We tested this possibility by transplanting 5x10 6 wild-type BM (CD45.2+) mononuclear cells into control or mutant animals (CD45.1+) following 7 doses of pIpC, but without irradiation ( Figure   S3D ). Indeed, minimal engraftment was observed in control mice as would be expected from the few available stem cell niches at homeostasis. In contrast, robust CD45.2+
donor engraftment was observed in mutant mice, with contribution to both myeloid and lymphoid lineages five months post-transplantation ( Figure S3D , red gate). These data further support HSPC impairment by Dicer loss and suggest HSC death caused by Dicer deficiency.
Taken together, the data above indicate that Dicer is necessary for HSPCs and its loss compromises HSPC function in a manner consistent with stem cell death.
A microRNA cluster preferentially expressed in LT-HSCs
Since microRNAs are major substrates for Dicer and microRNAs specify cellular states, we hypothesized that specific microRNAs contribute to the functional maintenance of a HSC state, as defined by persistent self-renewal capability coupled with multilineage differentiation capacity. To identify such microRNAs, we performed microRNA expression profiling in multiple stem cell and progenitor populations with well-defined markers using a bead-based expression analysis platform (6, 20) followed by RT-PCR validation ( Figure 2A and B, Figure S5A ). Interestingly, hierarchical clustering indicates that microRNA expression profiles reflect self-renewal and multipotency, with the more primitive populations clustered closely ( Figure 2A ). Specifically, we found multiple microRNAs preferentially expressed in populations that self-renew (Table S1 ). Of particular interest, three microRNAs, miR-99b, let-7e and miR-125a, were highly expressed in long-term (LT) HSCs compared to other populations ( Figure 2B and S5A).
These three microRNAs display a complete evolutionary conservation among mammals and organize in a cluster spanning a ~600 bp region on chromosome 19 in human and 17 in mice ( Figure S5B ).
We tested the function of the miR-99b-let-7e-miR-125a cluster in regulating HSCs using retroviral expression (vector also expresses GFP) followed by transplantation (20) . 
A single microRNA, miR-125a, augmented HSC activity
Individual microRNAs in the cluster were then analyzed. MiR-125a alone, but not miR99b or let-7e, provided comparable increase in long-term multi-lineage reconstitution ( Figure 3A , B, C and D). Remarkably, this enhancement appears to occur in the absence of a specialized BM microenvironment or niche, as 18-day ex vivo culture in the presence of miR-125a preserved robust stem cell activity, which was completely lost in the control cultures ( Figure 3E and S6B).
We next sought to determine if endogenous miR-125a regulates primitive hematopoietic cell function. To this end, we used antagomir against miR-125a, a chemically synthesized cell-permeable microRNA inhibitor (24) . This sequence-specific inhibitor of miR-125a did not affect methylcellulose colony morphology or numbers in primary cultures, but drastically reduced colony formation in subsequent serial replating cultures ( Figure 3F ). Since this assay is an in vitro surrogate for self-renewal, these data are consistent with miR-125a regulation of HSPC self-renewal.
MiR-125a amplifies the HSC pool size
To more precisely quantify the effect of miR-125a on stem cells, we performed the competitive limiting dilution assay (LDA). The need for this functional assay was substantiated by the observation that conventional stem cell surface markers were markedly changed with miR-125a ectopic expression, precluding accurate immunophenotypic enumeration. LDA analysis was performed using total GFP+ BM cells from recipients after 4-5 months in primary transplantation ( Table 1 ). The number of myeloid cells predominated with a reduced proportion of lymphoid cells (Table S2 and Figure   3D ). We scored both myeloid (Mac1+) and lymphoid lineages (B220+ or CD3+) in our LDA with ≥1% as cutoff. Although the apparent frequency of reconstituting HSCs varied between experiments (presumably due to different extent of HSC exhaustion under this experimental setting), we could consistently detect >8 fold expansion of the reconstituting HSC pool (Table 1) .
MiR-125a-induced stem cell amplification is cell-stage-specific
We next sought to determine if miR-125a expression confers self-renewal capacity regardless of the ground cell state. Figure 3G ) and through secondary transplantation (see limiting dilution assays Table 1 and S2). Similar results were obtained with further purified HSCs (LKSCD48-CD150+) as the starting population ( Figure 3H ). These results indicate that miR-125a
was insufficient to induce self-renewal in committed progenitors; its effect depends upon the underlying cell state.
MiR-125a protected primitive hematopoietic cells from apoptosis
Lastly, since Dicer loss induced apoptosis in HSPCs, we asked whether expression of miR-125a may protect primitive cells from apoptosis. BM from mice transplanted with control-or miR-125a-transduced cells were analyzed for apoptosis after reestablishment of homeostasis. We consistently observed decreased apoptosis in miR125a-tranduced cells in the lineage-negative population, but not in the more mature lineage-positive cells ( Figure 4A-B) , indicating a cell-type-specific effect of miR-125a.
These data are consistent with the anti-apoptotic effect being at least partially responsible for the increase in the reconstituting cell pool.
MiR-125a regulates the pro-apoptotic protein Bak1
Given the reduced apoptosis in primitive cells and the greatly expanded HSC pool size, we reasoned that miR-125a could target pro-apoptotic proteins to tilt the cellular balance of pro-and anti-apoptotic signals. miR-125a is predicted to target over 500 evolutionarily conserved targets (25) , a number of which have been reported with roles in apoptosis either directly or indirectly. We examined the pro-apoptotic protein, Bak1 (Bcl-2 antagonist/killer1). HL-60 or BaF3 cells were transduced with miR-125a or the control vector. In both cases, miR-125a expression reduced endogenous Bak1 protein by ~40-50% ( Figure 4C and S7A) . Scanning the 3' untranslated region (UTR) of Bak1 revealed one conserved miR-125a targeting site ( Figure S5C ). To ascertain whether the inhibitory effect of miR-125a was mediated through the specific target site in its 3'UTR, we fused the UTR sequence to a luciferase reporter. MiR-125a caused ~50% inhibition of the luciferase activity. In addition, mutation of the conserved targeting site alleviated most of the inhibition by miR-125a ( Figure 4D ). Consistent with the observation that miR-125a is the single microRNA within the miR-99b-let-7e-miR-125a cluster that mediates HSC expansion, miR-125a inhibited the Bak1 3'UTR construct ( Figure S7B ), whereas miR99b and let-7e had minimal effect.
We next asked whether forced expression of Bak1 could block miR-125a-mediated hematopoietic expansion. We co-expressed miR-125a with either control or Bak1 in donor marrow ( Figure 4E-F and S8 ). Co-expression events were marked with DsRedExpress and GFP double positive cells as miR-125a and Bak1 are expressed from vectors that also carry these two fluorescent proteins respectively. The percentages of all three populations increased during 6 days of in vitro culture. Although the increase for cells expressing Bak1 was always slower, Bak1 expressing cells were clearly detectable at all times and therefore the levels of Bak1 were not simply eliminating transduced cells ( Figure 4E and S8). Upon transplantation, miR-125a and control vector co-transduced marrow expanded as expected ( Figure 4F ). In contrast, donor marrow co-expressing miR-125a and Bak1 failed to contribute to PB at detectable levels, despite similar percentages of double positive cells 2 days after infection (1.12% and 1.02% for control and Bak1, respectively. Figure 4E ). This data demonstrate that sustained Bak1 expression blocks miR-125a-induced hematopoietic expansion. To evaluate whether blocking Bak1 mimics the effect of miR-125a, we examined HSCs in mice engineered to be deficient in Bak1 (26, 27) . We did not observe significant alteration in phenotypic and functional HSCs from Bak1 -/-marrows, suggesting either that miR-125a achieves hematopoietic expansion through targeting additional targets simultaneously (see discussion) or that the compensatory expression of Bak1 family members in the constitutive knock-out may obscure a more potent effect of Bak1.
Taken together, out data indicate that miR-125a protects HSPCs from apoptosis and promote extensive expansion of the hematopoietic stem cell pool.
DISCUSSION
We report an essential role of (25), it is certainly possible that their effect depends upon the combinatorial action of several molecules. Our data merely support that Bak1 is likely to be one of those molecules. This notion is supported by the fact that Bak1 -/-Bax -/-mice displayed increases in both myeloid and lymphoid lineages (27) . Indeed, we observed Puma (Bbc3) protein down-regulation by miR-125a in BaF3 cells, whereas BMF is a target for a miR-125a family member (35). While it is technically difficult to mimic the down-regulation of multiple anti-apoptotic proteins in HSCs simultaneously, we demonstrate that sustained Bak1 expression ablates the ability of miR-125a to induce hematopoietic expansion, supporting a role of the apoptotic pathway in mediating the effect of miR-125a. Recently, human p53 has been reported to be targeted by miR-125b
(36), a homolog of miR-125a. However, the targeting site identified in this study is not conserved in mouse, consistent with our observation of a lack of significant effect of miR-125a on mouse p53 3'UTR reporter. Hence p53 is an unlikely candidate that accounts for the superior HSC expansion seen with miR-125a.
In addition to the effect on stem cells and the amplification of all major lineages, we also noticed that sustained expression of miR-125a skewed lineage distribution, favoring the myeloid fate and compromising the B lymphoid fate ( Figure 3D and Table S2) .
Although the endogenous level of miR-125a is high in LT HSCs and much lower in progenitors, we do not exclude a role for miR-125a in committed hematopoietic progenitors, during lineage commitment or in more mature blood cells. Since HSCs are heterogeneous, it is also possible that miR-125a may have selectively expanded a more myelogenic subtype (designated α type HSC by Dykstra et al. (37)) or influenced other subtypes to be more α-like. We also note that miR-125b has been reported to be involved in leukemic translocation suggesting the possibility that this microRNA can participate in malignant hematopoiesis (38), although the mechanism and cell of origin remain to be investigated.
In summary, we report that microRNAs are actively participating in regulating the HSC state with sensitivity of HSPCs to the loss of the microRNA processing enzyme
Dicer and with the unique capability to have HSC number increased by a single microRNA, miR-125a. The ground state of the cell affects its response to microRNAs and suggest that microRNA-based cell modification may be a means to achieve stem cell specific therapeutics.
MATERIALS AND METHODS
The Subcommittee on Research Animal Care of the Massachusetts General Hospital approved all animal work. The Dicer lox/lox mice were described before (28) . All other mice were purchased from the Jackson Laboratory. Methylcellulose M3434 (StemCell Technologies) were used for colony forming assays. Luciferase reporter assay was preformed as described (20) . MicroRNA expression constructs were cloned into pMIRWAY-GFP as described (20) . Alternatively, GFP was replaced with DsRed-Express (Clonetech). For protein expression, the Bak1 open reading frame (ORF) was purchased from Invitrogen and subcloned into the pMIRWAY-GFP vector. Viral production, infection and bone marrow transplantation were performed as described (20) . Except where specified, all data are mean ± SD. p values were calculated using 2 tailed, unequal variance Student t test. More details for materials and methods are included in the Supporting Information.
Supporting Information
The Supporting Information includes eight figures and two tables. MicroRNA expression data have been deposited to GEO database. ║Certain animals were lost due to accidental dehydration. Initially 10 animals in group. 
